Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

From hydralazine to CGRP to man?

S B Field1, I A Burney, S Needham

  • 1MRC Cyclotron Unit, Hammersmith Hospital, London, UK.

International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
|May 1, 1994
PubMed
Summary

New vasoactive drugs, prazosin and CGRP, effectively reduce tumor blood flow without severe hypotension. Continuous CGRP infusion shows the most promise for cancer treatment by significantly lowering tumor blood flow with minimal systemic side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case of Perforation of the Stomach.

The London medical and physical journal·2018
Same author

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.

Journal of neurology, neurosurgery, and psychiatry·2017
Same author

Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes.

NMR in biomedicine·2016
Same author

Fracturing across the multi-scales of diverse materials.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2015
Same author

Dichloroacetate induces autophagy in colorectal cancer cells and tumours.

British journal of cancer·2014
Same author

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

British journal of cancer·2014

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Imaging

Background:

  • Selective reduction of tumor blood flow is a therapeutic strategy.
  • Hydralazine, a vasodilator, has shown limited clinical success due to severe systemic hypotension at effective doses.

Purpose of the Study:

  • To identify novel vasoactive drugs that reduce tumor blood flow without causing significant systemic blood pressure reduction.
  • To evaluate the efficacy of prazosin and CGRP in comparison to hydralazine.

Main Methods:

  • Magnetic resonance spectroscopy (MRS) was employed to assess tumor metabolism and blood flow.
  • Vasoactive drugs including hydralazine, prazosin, and CGRP were administered to animal models with transplanted tumors.
  • Studies also included radiation or chemically induced primary tumors.

Related Experiment Videos

Main Results:

  • Single injections of prazosin and CGRP significantly reduced tumor blood flow more effectively than hydralazine, with less impact on systemic blood pressure.
  • Continuous infusion of CGRP achieved a three-fold reduction in tumor blood flow with only a 15-20% decrease in systemic blood pressure.
  • Hydralazine showed a lower success rate (35%) in reducing blood flow in primary tumors compared to transplanted tumors (95%).

Conclusions:

  • Prazosin and CGRP represent promising alternatives to hydralazine for selective tumor blood flow reduction.
  • Continuous CGRP infusion offers a superior therapeutic window for reducing tumor perfusion with manageable systemic side effects.
  • Differences in drug response between primary and transplanted tumors warrant further investigation.